Antiretroviral therapy without nucleoside reverse transcriptase inhibitors: dual therapy with darunavir/p and rilpivirine. Safety and efficacy in clinical practice. RIDAR 2

被引：0
|
作者：
Arazo, P. [1 ]
Galindo, M. [2 ]
Montero, M. [3 ]
Tornero, C. [4 ]
Pasquau, J. [5 ]
机构：
[1] Hosp Miguel Servet, Infect Dis, Zaragoza, Spain
[2] Hosp Clin, Infect Dis, Valencia, Spain
[3] Hosp Univ & Politecn la Fe, Infect Dis, Valencia, Spain
[4] Hosp Francesc de Borja, Infect Dis, Gandia, Spain
[5] Hosp Virgen de las Nieves, Infect Dis, Granada, Spain
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P115
引用
收藏
页数：2
相关论文
共 29 条
  • [1] Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors:: indirect comparison of controlled trials
    Yazdanpanah, Y
    Sissoko, D
    Egger, M
    Mouton, Y
    Zwahlen, M
    Chêne, G
    BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7434): : 249 - 253
  • [2] Safety and efficacy of a raltegravir-based dual antiretroviral therapy in clinical practice
    Cenderello, G.
    Penco, G.
    Pontali, E.
    Feasi, M.
    Cassola, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 164 - 164
  • [3] Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection
    Vento, S
    Lanzafame, M
    Cainelli, F
    Faggian, F
    Concia, E
    Tositti, G
    Masiero, G
    AIDS, 2002, 16 (10) : 1432 - 1433
  • [4] Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: Protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors
    Tavel, JA
    Miller, KD
    Masur, H
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (03) : 643 - 676
  • [5] Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc
    Katiyar, A.
    Burns, F.
    Swaden, L.
    Youle, M.
    Barber, T. J.
    HIV MEDICINE, 2019, 20 : 63 - 63
  • [6] Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc
    Katiyar, A.
    Burns, F.
    Swaden, L.
    Youle, M.
    Barber, T.
    HIV MEDICINE, 2020, 21 : 16 - 16
  • [7] Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review
    Balayan, T.
    Horvath, H.
    Rutherford, G. W.
    HIV MEDICINE, 2019, 20 : 234 - 234
  • [8] Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy-Experienced Patients: A Multicenter Clinical Experience
    Gazzola, Lidia
    Cicconi, Paola
    Ripamonti, Diego
    Di Filippo, Elisa
    Gustinetti, Giulia
    Di Biagio, Antonio
    Marchetti, Giulia
    Bini, Teresa
    Monforte, Antonella d'Arminio
    HIV CLINICAL TRIALS, 2014, 15 (04): : 140 - 150
  • [9] Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors
    Lanier, ER
    Ait-Khaled, M
    Scott, J
    Stone, C
    Melby, T
    Sturge, G
    St Clair, M
    Steel, H
    Hetherington, S
    Pearce, G
    Spreen, W
    Lafon, S
    ANTIVIRAL THERAPY, 2004, 9 (01) : 37 - 45
  • [10] Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice
    Hoesley, CJ
    Saag, MS
    Chatham, A
    Kilby, JM
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (04) : 1095 - 1097
123